Skip to content

US-China Biomedical Technology, Inc.: 10-Q filed 2015-10-09

What US-China Biomedical Technology, Inc. reported in its quarterly report filed 2015-10-09 (fiscal Q2 2016): 14 published measures, 38 facts as tagged in accession 0001019687-15-003681.

This filing

Form
10-Q (quarterly report)
Filed
2015-10-09
Fiscal period
fiscal Q2 2016
Accession
0001019687-15-003681 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All US-China Biomedical Technology, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-08-31807USD
At 2015-02-2857,234USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-08-3145,549USD
At 2015-02-2888,084USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-08-31-44,742USD
At 2015-02-28-30,850USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-06-01 to 2015-08-31-23,222USD92
2015-03-01 to 2015-08-31-43,784USD184
2014-06-01 to 2014-08-31-75,488USD92
2014-03-01 to 2014-08-31-116,149USD184

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2015-06-01 to 2015-08-310USD92
2015-03-01 to 2015-08-310USD184
2014-06-01 to 2014-08-310USD92
2014-03-01 to 2014-08-310USD184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-08-31-1,685,695USD
At 2015-02-28-1,641,911USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2015-06-01 to 2015-08-310USD92
2015-03-01 to 2015-08-310USD184
2014-06-01 to 2014-08-310USD92
2014-03-01 to 2014-08-310USD184

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-03-01 to 2015-08-310USD184
2014-03-01 to 2014-08-3134,500USD184

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2015-08-3143,859USD
At 2015-02-2829,434USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-08-3113,026,980shares
At 2015-02-2813,026,980shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2015-08-311,627,926USD
At 2015-02-281,598,034USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2015-06-01 to 2015-08-31-23,222USD92
2015-03-01 to 2015-08-31-43,784USD184
2014-06-01 to 2014-08-31-75,488USD92
2014-03-01 to 2014-08-31-116,149USD184

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-06-01 to 2015-08-3123,222USD92
2015-03-01 to 2015-08-3143,784USD184
2014-06-01 to 2014-08-3175,488USD92
2014-03-01 to 2014-08-31116,149USD184

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2015-03-01 to 2015-08-3157,037USD184
2014-03-01 to 2014-08-310USD184

Inspect the source

Entity
US-China Biomedical Technology, Inc. / CIK 0001516079
Captured
SEC response SHA-256
c9cfb34f55b1d35452520c1453439439cbecbb44d0f2e8be8d980937632dd9ff

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001516079.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))